New hope for rare skin disease: first human trial of BCX17725 begins
NCT ID NCT06539507
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 20 times
Summary
This early-stage study tests a new drug called BCX17725 for Netherton syndrome, a rare genetic condition that causes severe skin redness and scaling. The trial first checks safety in healthy adults, then tests the drug in people with the condition to see if it improves skin symptoms. About 78 participants, including teens and adults, will take part over 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NETHERTON SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dawes Fretzin Clinical Research Group, LLC
RECRUITINGIndianapolis, Indiana, 46250, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Erasmus Universitair Medisch Centrum (EMC)
RECRUITINGRotterdam, 3015 GD, Netherlands
-
Hôpital Saint-Louis
NOT_YET_RECRUITINGParis, 75010, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Maastricht Universitair Medisch Centrum (MUMC+)
NOT_YET_RECRUITINGMaastricht, 6229 HX, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwestern Dermatology CTU
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nucleus Network
ACTIVE_NOT_RECRUITINGBrisbane, Queensland, 4006, Australia
-
Stanford University School of Medicine
NOT_YET_RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Therapeutics Clinical Research
RECRUITINGSan Diego, California, 92123, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsklinikum Heidelberg
NOT_YET_RECRUITINGHeidelberg, 69120, Germany
-
Veracity Clinical Research
RECRUITINGBrisbane, Queensland, 4102, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Westmead Hospital - Department of Dermatology
RECRUITINGSydney, New South Wales, 2145, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale Center for Clinical Investigation
RECRUITINGNew Haven, Connecticut, 06519, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.